{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:26Z","timestamp":1793048786505,"version":"4.5.0"},"reference-count":90,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/14728214.2023.2221028","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:45:24Z","timestamp":1685555124000},"page":"153-165","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Systemic mastocytosis: 2023 update on diagnosis and management in adults"],"prefix":"10.1080","volume":"28","author":[{"given":"Alessandro","family":"Costa","sequence":"first","affiliation":[{"name":"Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Carmosino","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Capriata","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ielo","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Masucci","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Passucci","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-0339","authenticated-orcid":false,"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent P","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420\u20131427.","journal-title":"Blood"},{"key":"e_1_3_4_4_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00620","article-title":"Mast cell: a multi-functional master cell","volume":"6","author":"Krystel-Whittemore M","year":"2016","unstructured":"Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol. 2016;6. [[cited 2023 Mar 1]]. InternetAvailable from: http:\/\/journal.frontiersin.org\/Article\/10.3389\/fimmu.2015.00620\/abstract","journal-title":"Front Immunol"},{"key":"e_1_3_4_5_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u20132405.","journal-title":"Blood"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u20131228.","journal-title":"Blood"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205237"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11588890-000000000-00000"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.02.002"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048188"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.011"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524532"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000048180"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2014.955008"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006157"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase\u2013encoding germline copy number at TPSAB1","volume":"147","author":"Lyons JJ","year":"2021","unstructured":"Lyons JJ, Chovanec J, O\u2019Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase\u2013encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021;147:622\u2013632.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000646"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V91.4.1101","article-title":"C-kit ligand and Flt3 Ligand: stem\/progenitor cell factors with overlapping yet distinct activities","volume":"91","author":"Lyman SD","year":"1998","unstructured":"Lyman SD, Jacobsen SEW. C-kit ligand and Flt3 Ligand: stem\/progenitor cell factors with overlapping yet distinct activities. Blood. 1998;91:1101\u20131134.","journal-title":"Blood"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Clark SC","year":"2021","unstructured":"Clark SC, Sprinzl B, G\u00f3rska A. Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021;137:238\u2013247.","journal-title":"Blood"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/j.1460-2075.1991.tb07784.x","article-title":"Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase","volume":"10","author":"Reith AD","year":"1991","unstructured":"Reith AD, Ellis C, Lyman SD, et al. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. Embo J. 1991;10:2451\u20132459.","journal-title":"Embo J"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jaci.2022.04.004","article-title":"Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: status 2022","volume":"149","author":"Arock M","year":"2022","unstructured":"Arock M, Hoermann G, Sotlar K, et al. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: status 2022. J Allergy Clin Immunol. 2022;149:1855\u20131865.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031521-042618"},{"key":"e_1_3_4_23_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bjh.17405","article-title":"Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series","volume":"193","author":"Tanasi I","year":"2021","unstructured":"Tanasi I, Bonifacio M, Pizzolato M, et al. Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. Br J Haematol. 2021;193:845\u2013848.","journal-title":"Br J Haematol"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24426"},{"key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab J","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460\u20132466.","journal-title":"Blood"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.24"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.37"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u20131719.","journal-title":"Leukemia"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071420"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2677"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23380"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.09.010"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"\u00c1lvarez-Twose I","year":"2016","unstructured":"\u00c1lvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168\u2013178.e1.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004934"},{"key":"e_1_3_4_35_1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ajh.24382","article-title":"Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients: a Survey on 460 patients with systemic mastocytosis","volume":"91","author":"Pieri L","year":"2016","unstructured":"Pieri L, Bonadonna P, Elena C, et al. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients: a Survey on 460 patients with systemic mastocytosis. Am J Hematol. 2016;91:692\u2013699.","journal-title":"Am J Hematol"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14248"},{"key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized management strategies in mast cell disorders: eCNM-AIM user\u2019s guide for daily clinical practice","volume":"10","author":"Valent P","year":"2022","unstructured":"Valent P, Hartmann K, Schwaab J, et al. Personalized management strategies in mast cell disorders: eCNM-AIM user\u2019s guide for daily clinical practice. J Allergy Clin Immunol Pract. 2022;10:1999\u20132012.e6.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.12.030"},{"key":"e_1_3_4_39_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano L","year":"2009","unstructured":"Escribano L, \u00c1lvarez-Twose I, S\u00e1nchez-Mu\u00f1oz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514\u2013521.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3283366c59"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01406-y"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018026245"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0189-5"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30166-8"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30400-2"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00640"},{"key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani A","year":"2013","unstructured":"Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood. 2013;121:3085\u20133094.","journal-title":"Blood"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.03.032"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13592"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21561"},{"key":"e_1_3_4_51_1","doi-asserted-by":"crossref","unstructured":"Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Hematology ASH Education Program American Society of Hematology [Internet]. [cited 2023 Mar 15]. Available from: https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/34\/493554\/Available-and-emerging-therapies-for-bona-fide","DOI":"10.1182\/hematology.2022000368"},{"key":"e_1_3_4_52_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo DJ","year":"2018","unstructured":"DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32:470\u2013478.","journal-title":"Leukemia"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.06.003"},{"key":"e_1_3_4_54_1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo DJ","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27:2183\u20132191.","journal-title":"Nat Med"},{"key":"e_1_3_4_55_1","unstructured":"Radia D Avapritinib as first-line therapy in patients with advanced systemic mastocytosis: efficacy and safety from the pathfinder clinical study. ASH; 2022 [cited 2023 Mar 12]. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper166986.html"},{"key":"e_1_3_4_56_1","doi-asserted-by":"crossref","unstructured":"Akin C Results from pioneer: a randomized double-blind placebo-controlled phase 2 study of avapritinib in patients with indolent systemic mastocytosis. ASH; 2020 [cited 2023 Mar 12]. Available from: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper139367.html.","DOI":"10.1016\/j.jaci.2019.12.062"},{"key":"e_1_3_4_57_1","unstructured":"Additional PIONEER study results back FDA priority review for avapritinib in indolent systemic mastocytosis [Internet]. Target. Oncol. 2023 [cited 2023 Mar 12]. Available from: https:\/\/www.targetedonc.com\/view\/additional-pioneer-study-results-back-fda-priority-review-for-avapritinib-in-indolent-systemic-mastocytosis"},{"key":"e_1_3_4_58_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk HJ","year":"2006","unstructured":"Droogendijk HJ, Kluin-Nelemans HJC, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107:345\u2013351.","journal-title":"Cancer"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.12.020"},{"key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose I","year":"2017","unstructured":"Alvarez-Twose I, Matito A, Morgado JM, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2017;8:68950\u201368963.","journal-title":"Oncotarget"},{"key":"e_1_3_4_61_1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul C","year":"2010","unstructured":"Paul C, Sans B, Suarez F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010;85:921\u2013925.","journal-title":"Am J Hematol"},{"key":"e_1_3_4_62_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary O","year":"2017","unstructured":"Lortholary O, Chandesris MO, Livideanu CB, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017;389:612\u2013620.","journal-title":"Lancet"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.018"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91439-8_10"},{"key":"e_1_3_4_65_1","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib J","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530\u20132541.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26498"},{"key":"e_1_3_4_67_1","doi-asserted-by":"crossref","unstructured":"Papayannidis C Real-World management of advanced systemic mastocytosis treated with midostaurin: analysis of patients who completed 12 months of follow-up from an Italian observational study (OVIDIO). ASH; 2022 [cited 2023 Mar 11]. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper156371.html.","DOI":"10.1182\/blood-2022-156371"},{"key":"e_1_3_4_68_1","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26464","article-title":"Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience","volume":"97","author":"Farrukh F","year":"2022","unstructured":"Farrukh F, Gangat N, Shah MV, et al. Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience. Am J Hematol. 2022;97 [[cited 2023 Mar 12]]. InternetAvailable from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26464","journal-title":"Am J Hematol"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014612"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007539"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15673"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.020"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.046"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14115-3"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.04.003"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13163"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15262"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030469"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT122"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846936.51452.f2"},{"key":"e_1_3_4_81_1","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1182\/blood-2022-167410","article-title":"AZURE: a phase 1\/2 study of Blu-263 as monotherapy and in combination with azacitidine in patients with advanced systemic mastocytosis","volume":"140","author":"DeAngelo DJ","year":"2022","unstructured":"DeAngelo DJ, Reiter A, George TI, et al. AZURE: a phase 1\/2 study of Blu-263 as monotherapy and in combination with azacitidine in patients with advanced systemic mastocytosis. Blood. 2022;140:6877\u20136878.","journal-title":"Blood"},{"key":"e_1_3_4_82_1","doi-asserted-by":"crossref","unstructured":"Akin C Summit: a 3-part phase 2 study of Bezuclastinib (CGT9486) an Oral selective and potent KIT D816V Inhibitor in adult patients with nonadvanced systemic mastocytosis (NonAdvsm). ASH; 2022 [cited 2023 Mar 14]. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper156326.html","DOI":"10.1182\/blood-2022-156326"},{"key":"e_1_3_4_83_1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2022-156311","article-title":"Preliminary safety and efficacy from Apex, a phase 2 study of Bezuclastinib (CGT9486), a Novel, Highly selective, potent KIT D816V Tyrosine Kinase inhibitor, in adults with advanced systemic mastocytosis (AdvSM)","volume":"140","author":"DeAngelo DJ","year":"2022","unstructured":"DeAngelo DJ, Pullarkat VA, Piris-Villaespesa M, et al. Preliminary safety and efficacy from Apex, a phase 2 study of Bezuclastinib (CGT9486), a Novel, Highly selective, potent KIT D816V Tyrosine Kinase inhibitor, in adults with advanced systemic mastocytosis (AdvSM). Blood. 2022;140:1512\u20131513.","journal-title":"Blood"},{"key":"e_1_3_4_84_1","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2021-152770","article-title":"Preclinical Data with KIT D816V inhibitor Bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance","volume":"138","author":"Guarnieri A","year":"2021","unstructured":"Guarnieri A, Chicarelli M, Cable L, et al. Preclinical Data with KIT D816V inhibitor Bezuclastinib (CGT9486) demonstrates high selectivity and minimal brain penetrance. Blood. 2021;138:4595\u20134595.","journal-title":"Blood"},{"key":"e_1_3_4_85_1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3324\/haematol.2017.179895","article-title":"The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis","volume":"103","author":"Schneeweiss M","year":"2018","unstructured":"Schneeweiss M, Peter B, Bibi S, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018;103:799\u2013809.","journal-title":"Haematologica"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"e_1_3_4_87_1","unstructured":"Toledo MAS Gatz M Sontag S et al. Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis."},{"issue":"2","key":"e_1_3_4_88_1","first-page":"355","article-title":"Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study","volume":"13","author":"Degenfeld-Schonburg L","year":"2003","unstructured":"Degenfeld-Schonburg L, Gamperl S, Stefanzl G, et al. Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study. Am J Cancer Res. 2003;13(2):355\u2013378.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_89_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings SV","year":"2018","unstructured":"Jennings SV, Slee VM, Zack RM, et al. Patient perceptions in mast cell disorders. Immunol Allergy Clin North Am. 2018;38:505\u2013525.","journal-title":"Immunol Allergy Clin North Am"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.03.001"},{"key":"e_1_3_4_91_1","article-title":"Challenges in applying diagnostic criteria for systemic mastocytosis","author":"Boggs NA","year":"2023","unstructured":"Boggs NA, Sun X, Lyons JJ, et al. Challenges in applying diagnostic criteria for systemic mastocytosis. Blood Adv. 2023.","journal-title":"Blood Adv"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01442-2"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2023.2221028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:18:23Z","timestamp":1697095103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2023.2221028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/14728214.2023.2221028"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2023.2221028","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}